KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Gross Profit (2017 - 2025)

Aquestive Therapeutics has reported Gross Profit over the past 9 years, most recently at $20.0 million for Q4 2025.

  • Quarterly results put Gross Profit at $20.0 million for Q4 2025, up 172.18% from a year ago — trailing twelve months through Dec 2025 was $38.8 million (down 2.22% YoY), and the annual figure for FY2025 was $38.8 million, down 2.22%.
  • Gross Profit for Q4 2025 was $20.0 million at Aquestive Therapeutics, up from $8.3 million in the prior quarter.
  • Over the last five years, Gross Profit for AQST hit a ceiling of $20.0 million in Q4 2025 and a floor of -$2.5 million in Q2 2021.
  • Median Gross Profit over the past 5 years was $7.7 million (2021), compared with a mean of $7.7 million.
  • Biggest five-year swings in Gross Profit: soared 769.57% in 2021 and later crashed 65.05% in 2025.
  • Aquestive Therapeutics' Gross Profit stood at $7.7 million in 2021, then crashed by 30.28% to $5.4 million in 2022, then surged by 43.65% to $7.7 million in 2023, then decreased by 4.88% to $7.3 million in 2024, then skyrocketed by 172.18% to $20.0 million in 2025.
  • The last three reported values for Gross Profit were $20.0 million (Q4 2025), $8.3 million (Q3 2025), and $5.4 million (Q2 2025) per Business Quant data.